ArticleScientific reports2025
SMP30 May protect human lens epithelial cells against high glucose-induced oxidative damage by regulating the Keap1/Nrf2/NQO1 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mulberroside A attenuates HMolecular medicine reports · 2026Article
- Article
- SMP30: a promising cancer biomarker with therapeutic potential.Open medicine (Warsaw, Poland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this study was to explore the role and mechanism of SMP30 in diabetic cataract(DC) patients with different glycemic control levels and high glucose-stimulated human lens epithelial cells. First, aqueous humor and lens anterior capsules were collected during cataract surgery. Second, human lens epithelial B3(HLE-B3) cells were stimulated with different glucose concentrations. Then, SMP30-overexpressing plasmids were transfected into HLE-B3 cells. Measured blood and aqueous humor glucose concentrations in cataract patients. Oxidative stress levels was assessed by analyzing SOD, MDA and ROS. The mRNA and protein expression levels of SMP30 and Keap1/Nrf2/NQO1 pathway factors were detected. The cell viability was analyzed. The glucose concentration in blood and aqueous humor increased, and MDA content increased and SOD activity decreased in DC patients with poor glycemia control. However, SMP30 expression was upregulated of these patients, in parallel with the possible activation of Keap1/Nrf2/NQO1 pathway. The MDA content and ROS levels increased, and SOD activity decreased under high glucose(40 mM, 60 mM) in HLE-B3 cells. Meanwhile, SMP30 expression was up-regulated and Keap1/Nrf2/NQO1 pathway was activated at a glucose of 20 mM, but down-regulated and Keap1/Nrf2/NQO1 pathway was inhibited at a glucose of 40 mM or 60 mM. Overexpression of SMP30 reduced the oxidative stress damage and increased the cell viability, and reversed the expression of Keap1/Nrf2/NQO1 pathway factors induced by high glucose in HLE-B3. This study demonstrates that SMP30 may protect human lens epithelial cells from high glucose-stimulated oxidative stress damage and may involves the regulation of Keap1/Nrf2/NQO1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.